Synthesis and anti-Paracoccidioides activity of calix[n]arenes

Letters in Drug Design and Discovery

Volumn 9, Issue 1, 2012, Pages 30-36

  De Oliveira, Marcilene Coimbra ^a   Reis, Fabiano Souza ^a   De Fátima, Ângelo ^a   Magalhães, Thais Furtado Ferreira ^a   Da Silva, Danielle Letícia ^a   Porto, Raphael Rodrigues ^a   Watanabe, Giselle Almeida ^a   Martins, Cleide Viviane Buzanello ^b   Da Silva, Daniel Leite ^a   Ruiz, Ana Lúcia Tasca Góis ^c   Fernandes, Sergio Antonio ^d   De Carvalho, João Ernesto ^c   De Resende Stoianoff, Maria Aparecida ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSIDADE ESTADUAL DO OESTE DO PARANÁ   (Brazil)

^c UNIVERSITY OF CAMPINAS   (Brazil)

^d FEDERAL UNIVERSITY OF VIÇOSA   (Brazil)

Author keywords

Antifungal; Calix n arenes; Dimorphic fungi; Mammalian cells; P tert butylcalix n arene; Paracoccidioides genus; Paracoccidioidomycosis

Indexed keywords

ANTIFUNGAL AGENT; CALIXARENE; P TERT BUTYLCALIX 1 ARENE; P TERT BUTYLCALIX 3 ARENE; P TERT BUTYLCALIX 4 ARENE; P TERT BUTYLCALIX 5 ARENE; P TERT BUTYLCALIX 6 ARENE; P TERT BUTYLCALIX 8 ARENE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOG; FUNGAL CELL; HAMSTER; LUNG; MAMMAL CELL; NONHUMAN; PARACOCCIDIOIDES BRASILIENSIS; PETRIELLIDIUM BOYDII; PRIORITY JOURNAL; SOUTH AMERICAN BLASTOMYCOSIS;

EID: 84858987449     PISSN: 15701808     EISSN: 1875628X     Source Type: Journal    
DOI: 10.2174/157018012798192991     Document Type: Article

References (38)

1. Sundriyal, S.; Sharma, R.K.; Jain, R. Current advances in antifungal targets and drug development. Curr. Med. Chem. 2006, 13, 1321-1335.
2. Andriole, V.T. Current and future antifungal therapy: new targets for antifungal agents. J. Antimicrob. Chemother. 1999, 44, 151-162. (Pubitemid 29389278)
3. Ascioglu, S.; Rex, J.H.; de Pauw, B.; Bennett, J.E.; Bille, J.; Crokaert, F.; Denning, D.W.; Donnelly, J.P.; Edwards, J.E.; Erjavec, Z.; Fiere, D.; Lortholary, O.; Maertens, J.; Meis, J.F.; Patterson T.F.; Ritter, J.; Selleslag, D.; Shah, P.M.; Stevens, D.A.; Walsh, T.J. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin. Infect. Dis. 2002, 34, 7-14. (Pubitemid 33152659)
4. Nucci, M.; Marr, K.A. Emerging fungal diseases. Clin. Infect. Dis. 2005, 41, 521-526. (Pubitemid 41099648)
5. Borges-Walmsley, M.I.; Chen, D.; Shu, X.; Walmsley, A.R. The pathobiology of Paracoccidioides brasiliensis. Trends in Microbiol. 2002, 10, 80-87. (Pubitemid 34119344)
6. Teixeira, M.M.; Theodoro, R.C.; de Carvalho, M.J.A.; Fernandes, L.; Paes, H.C.; Hahn, R.C.; Mendoza, L.; Bagagli, E.; San-Blas, G.; Felipe, M.S.S. Phylogenetic analysis reveals a high level of speciation in the Paracoccidioides genus. Mol. Phylogen. Evol. 2009, 52, 273-283.
7. Brummer, E.; Castaneda, E.; Restrepo, A. Paracoccidioidomycosis: an update. Clin. Microbiol. Rev. 1993, 6, 89-117.
8. Hahn, R.C.; Hamdan, J.S. Effects of amphotericin B and three azole derivatives on the lipids of yeast cells of Paracoccidioides brasiliensis. Antimicrob. Agents Chemother. 2000, 44, 1997-2000. (Pubitemid 30422965)
9. Prado, M.; da Silva, M.B.; Laurenti, R.; Travassos, L.R.; Taborda, C.P. Mortality due to systemic mycoses as a primary cause of death or in association with AIDS in Brazil: a review from 1996 to 2006. Mem. Inst. Oswaldo Cruz 2009, 104, 513-521.
10. de Fátima, A.; Fernandes, S.A.; Sabino, A.A. Calixarenes as new platforms for drug design. Curr. Drug Discov. Technol. 2009, 6, 151-170.
11. Perret, F.; Lazar, A.N.; Coleman, A.W. Biochemistry of the para-sulfonato-calix[n]arenes. Chem. Commun. 2006, 23, 2425-2438. (Pubitemid 43877069)
12. Motornaya, A.E.; Alimbarova, L.M.; Shokova, E.A.; Kovalev, V.V. Synthesis and antiherpetic activity of N-(3-amino-1-adamantyl)calix[4]arenes. Pharm. Chem. J. 2006, 40, 68-72.
13. Mourer, M.; Psychogios, N.; Laumond, G.; Aubertin, A.M.; Regnouf-de-Vains, J.B. Synthesis and anti-HIV evaluation of water-soluble calixarene-based bithiazolyl podands. Bioorg. Med. Chem. 2010, 18, 36-45.
14. Geller, C.; Fontanay, S.; Mourer, M.; Dibama, H.M.; Regenouf-de-Vains, J.B.; Finance, C.; Duval, R.E. Antiseptic properties of two calix[4]arenes derivatives on the human coronavirus 229E. Antiviral Res. 2010, 88, 343-346.
15. Tsou, L.K.; Dutschman, G.E.; Gullen, E.A.; Telpoukhovskaia, M.; Cheng, Y.C.; Hamilton, A. Discovery of a synthetic dual inhibitor of HIV and HCV infection based on a tetrabutoxy-calix[4]arene scaffold. Bioorg. Med. Chem. Lett. 2010, 20, 2137-2139.
16. Consoli, G.M.L.; Granata, G.; Galante, E.; Silvestro, I.D.; Salafia, L.; Geraci, C. Synthesis of water-soluble nucleotidecalixarene conjugates and preliminary investigation of their in vitro DNA replication inhibitory activity. Tetrahedron 2007, 63, 10758-10763. (Pubitemid 47418882)
17. Casnati, A.; Fabbi, M.; Pelizzi, N.; Pochini, A.; Sansone, F.; Ungaro, R. Synthesis, antimicrobial activity and binding properties of calix[4]arene basedvancomycin mimics. Bioorg. Med. Chem. Lett. 1996, 6, 2699-2704. (Pubitemid 26387249)
18. Lamartine, R.; Tsukada, M.; Wilson, D.; Shirata, A. Antimicrobial activity of calixarenes. C. R. Chimie 2002, 5, 163-169. (Pubitemid 36395779)
19. Mourer, M.; Duval, R.E.; Finance, C.; Regnouf-de-Vains, J.B. Functional organisation and gain of activity: The case of the antibacterial tetra-para-guanidinoethyl-calix[4]arene. Bioorg. Med. Chem. Lett. 2006, 16, 2960-2963.
20. Grare, M.; Dibama, H.M.; Lafosse, S.; Ribon, A.; Mourer, M.; Regnouf-de-Vains, J.B.; Finance, C.; Duval, R.E. Cationic compounds with activity against multidrug-resistant bacteria: interest of a new compound compared with two older antiseptics, hexamidine and chlorhexidine. Clin. Microbiol. Infect. 2010, 16, 432-438.
21. Grare, M.; Mourer, M.; Fontanay, S.; Regnouf-de-Vains, J.B.; Finance, C.; Duval, R.E. In vitro activity of para-guanidinoethylcalix[4]arene against susceptible and antibiotic-resistant Gram-negative and Gram-positive bacteria. J. Antimicrob. Chemother. 2007, 60, 575-581. (Pubitemid 47299871)
22. Paquet, V.; Zumbuehl, A.; Carreira, E.M. Biologically active amphotericin B-calix[4]arene conjugates. Bioconjugate Chem. 2006, 17, 1460-1463. (Pubitemid 44851490)
23. Zhou, H.; Wang, D.; Baldini, L.; Ennis, E.; Jain, R.; Carie, A.; Sebti, S.M.; Hamilton, A.D. Structure-activity studies on a library of potent calix[4]arene-based PDGF antagonists that inhibit PDGF-stimulated PDGFR tyrosine phosphorylation. Org. Biomol. Chem. 2006, 4, 2376-2386. (Pubitemid 43882759)
24. Dings, R.P.M.; Chen, X.; Hellebrekers, D.M.E.I.; van Eijk, L.I.; Zhang, Y.; Hoye, T.R.; Griffioen, A.W.; Mayo, K.H. Design of nonpeptidic topomimetics of antiangiogenic proteins with antitumor activities. J. Natl. Cancer Inst. 2006, 98, 932-936. (Pubitemid 44018923)
25. Martins, C.V.B.; da Silva, D.L.; Neres, A.T.M.; Magalhães, T.F.F.; Watanabe, G.A.; Modolo, L.V.; Sabino, A.A.; de Fátima, A.; de Resende, M.A. Curcumin as a promising antifungal of clinical interest. J. Antimicrob. Chemother. 2009, 63, 337-339.
26. Martins, C.V.B.; de Resende, M.A.; da Silva, D.L.; Magalhães, T.F.F.; Modolo, L.V.; Pilli, R.A.; de Fátima, A. In vitro studies of anticandidal activity of goniothalamin enantiomers. J. Appl. Microbiol. 2009, 107, 1279-1286.
27. Martins, C.V.B.; de Resende, M.A.; Magalhães, T.F.F.; Lima, B.H.S.; Watanabe, G.A.; Ruiz, A.L.T.G.; de Carvalho, J.E.; Pilli, R.A.; de Fátima, A. Antifungal activity of goniothalamin enantiomers. Lett. Drug Design Disc. 2008, 5, 74-78.
28. Gutsche, C.D.; Bauer, L.J. Calixarenes. 5. Dynamic NMR characteristics of p-tert-butylcalix[4]-arene and p-tert-butylcalix[8]arene. Tetrahedron Lett. 1981, 22, 4763-4766.
29. Gutsche, C.D.; Iqbal, M. p-tert-Butylcalix[4]arene. Org. Synth. 1990, 68, 234-237.
30. Gutsche, C.D.; Alam, I.; Iqbal, M.; Mangiafico, T.; Nam, K.C.; Rogers, J.; See, K.A. Topics in calixarene chemistry. J. Inclusion Phenom. Macrocyclic Chem. 1989, 7, 61-72.
31. Gutsche, C.D.; Lin, L.G. Calixarenes 12 : The synthesis of functionalized calixarenes. Tetrahedron 1986, 42, 1633-1640.
32. Yi, J.; Huang, S.; Tang, K.; Huang, K. Synthesis of calixarenes and their extraction performance for ester catechins. J. Cent. South Univ. Technol. 2007, 14, 798-802.
33. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard, 2nd edn. NCCLS document M27-A2. Villanova: Clinical and Laboratory Standards Institute, 2002.
34. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard, 2nd edn . NCCLS document M27-A2. Villanova: Clinical and Laboratory Standards Institute, 2002.
35. Johann, S.; Cisalpino, P.S.; Watanabe, G.A.; Cota, B.B.; de Siqueira, E.P.; Pizzolatti, M.G.; Zani, C.L.; de Resende, M.A. Antifungal activity of extracts of some plants used in Brazilian traditional medicine against the pathogenic fungus Paracoccidioides brasiliensis. Pharm. Biol. 2010, 48, 388-396.
36. Hahn, R.C.; Hamdan, J.S. In vitro susceptibilities of Paracoccidioides brasiliensis yeast form to antifungal drugs. Mycoses 2000, 43, 403-407. (Pubitemid 32055283)
37. Espinel-Ingroff, A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. 1998, 36, 2950-2963.
38. Monks, A.; Scudiero, D.; Skehan, P.; Shoemaker, R.; Paull, K.; Vistica, D.; Hose, C.; Langley, J.; Cronise, P.; Vaigro-Wolff, A.; Gray-Goodrich, M.; Campbell, H.; Mayo, J.; Boyd, M. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Nat. Cancer Inst. 1991, 83, 757-766.